Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F, Lankes K, Schneeweis C, Hassan Z, Jakubowsky H, Krauß L, Boniolo F, Schneider C, Schäfer A, Murr J, Schlag C, Kong B, Öllinger R, Wang C, Beyer G, Mahajan UM, Xue Y, Mayerle J, Schmid RM, Kuster B, Rad R, Braun CJ, Wirth M, Reichert M, Saur D, Schneider G.
Orben F, et al. Among authors: beyer g.
JCI Insight. 2022 May 23;7(10):e151353. doi: 10.1172/jci.insight.151353.
JCI Insight. 2022.
PMID: 35439169
Free PMC article.